By Nqobile Dludla and Siyanda Mthethwa JOHANNESBURG (Reuters) -Danish drugmaker Novo Nordisk introduced its weight-loss drug ...

Semaglutide and similar peptide drugs bind the G-protein coupled GLP-1 receptor to transfer chemical signals from outside the ...

Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out the middlemen.

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its ...

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

In this week’s InnovationRx newsletter, we look at longevity drugs for dogs, programmable mRNA for fighting cancer, AI models ...

What Happened: Skovronsky demonstrated confidence in Eli Lilly by purchasing 1,000 shares, as reported in a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday. The total value ...

What Happened: file made a significant move by purchasing 1,565 shares of Eli Lilly as reported in a Form 4 filing with the U.S. Securities and Exchange Commission. The transaction's total worth ...

Texas AG Ken Paxton sues Eli Lilly for alleged bribery to promote diabetes drugs, claiming violation of state fraud laws and ...

Patients on Eli Lilly's new oral medication orforglipron lost an average of 12.4% of their body weight over 72 weeks.

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant ...